医学
肝切除术
肝移植
阶段(地层学)
结直肠癌
内科学
胃肠病学
移植
肿瘤科
外科
切除术
癌症
生物
古生物学
作者
Yosuke Nakao,René Adam,Abdul Halim Nasser,Katsunori Imai,Nicolas Golse,Daniel Pietrasz,Oriana Ciacio,Gabriella Pittau,Chady Salloum,Masaaki Iwatsuki,Éric Vibert,António Sá Cunha,Françis Lévi,Michel Ducreux,Maximiliano Gelli,M. Lewin,Hideo Baba,Daniel Cherqui,Daniel Azoulay,Marc‐Antoine Allard
出处
期刊:Annals of Surgery
[Lippincott Williams & Wilkins]
日期:2025-08-12
卷期号:283 (3): 365-374
被引量:2
标识
DOI:10.1097/sla.0000000000006904
摘要
OBJECTIVE: To compare outcomes after two-stage hepatectomy (TSH) or liver transplantation (LT) in patients with extensive bilobar colorectal liver metastases (CRLM). BACKGROUND: Given the high rate of intrahepatic recurrence after TSH in patients with resectable but extensive bilobar CRLM, LT may be an alternative option. However, studies comparing TSH for potentially resectable patients to LT for unresectable ones are lacking. METHODS: We compared oncological outcomes of consecutive patients who underwent TSH for extensive bilobar CRLM (resection group, n=32) without extrahepatic disease with those of all patients who underwent LT for unresectable liver-only CRLM (LT group, n=19) at a single center within the 2016 to 2023 period. Results were analysed both in intention to treat and in per protocol. Propensity score matching (PSM) was used to refine the comparability of both groups. RESULTS: The baseline and biological tumor characteristic of both groups were comparable except for unresectability and higher number of lesions in the LT group. Overall survival (OS), recurrence-free survival (RFS), and time to surgical failure (TSF) in the LT group were all significantly better than those in the TSH group (5-year OS: 84% vs 32%, P =0.003, 5-year RFS: 24% vs 0%, P =0.0001, 5-year TSF: 61% vs 7.7%, P <0.0001). Multivariable analysis revealed that left primary sidedness [hazard ratio (HR): 0.38, P =0.049] and LT (HR: 0.20, P =0.01) were independent prognostic factors of favorable OS. These results were confirmed after PSM. CONCLUSIONS: Our results suggest that LT might achieve better outcomes than TSH in patients with extensive bilobar but resectable liver-only CRLM.
科研通智能强力驱动
Strongly Powered by AbleSci AI